Vaccentis attends LSX conference in London and presents the core business strategy for the oncological tumor vaccine VCC-001 and pipeline platfrom to investors.
Vaccentis attends LSX conference in London and presents the core business strategy for the oncological tumor vaccine VCC-001 and pipeline platfrom to investors.
Vaccentis AG,
Gerechtigkeitsgasse 25, CH - 8001 Zürich